Atezolizumab y bevacizumab en carcinoma hepatocelular irresecable

Arias Z, Rodrigo; Gándara F, Vicente; Seydewitz O, María Francisca; Tortorolo C, Francisco; Benítez G, Carlos

Atezolizumab y bevacizumab en carcinoma hepatocelular irresecable / Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Arias Z, Rodrigo; Gándara F, Vicente; Seydewitz O, María Francisca; Tortorolo C, Francisco; Benítez G, Carlos.

Affiliation

Arias Z, Rodrigo; Pontificia Universidad Católica de Chile. Escuela de Medicina. Santiago. CL
Gándara F, Vicente; Pontificia Universidad Católica de Chile. Escuela de Medicina. Santiago. CL
Seydewitz O, María Francisca; Pontificia Universidad Católica de Chile. Escuela de Medicina. Santiago. CL
Tortorolo C, Francisco; Pontificia Universidad Católica de Chile. Departamento de Gastroenterología. Santiago. CL
Benítez G, Carlos; Pontificia Universidad Católica de Chile. Departamento de Gastroenterología. Santiago. CL

Gastroenterol. latinoam ; 32(1): 24-32, 2021. tab

Article in Spanish | LILACS | ID: biblio-1352385

Responsible library: CL61.1

Subject(s)

Humans; Carcinoma, Hepatocellular/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use; Bevacizumab/therapeutic use; Liver Neoplasms/drug therapy; Quality of Life; Survival Analysis

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Collection: International databases Database: LILACS Main subject: Carcinoma, Hepatocellular / Antibodies, Monoclonal, Humanized / Bevacizumab / Liver Neoplasms Aspects: Patient-preference Limits: Humans Language: Spanish Journal: Gastroenterol. latinoam Journal subject: Gastroenterology Year: 2021 Document type: Article Affiliation country: Chile Institution/Affiliation country: Pontificia Universidad Católica de Chile/CL

Fulltext

Add to My VHL

XML

Search on Google